HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Usefulness of quantifying serum KL-6 levels in the follow-up of uveitic patients with sarcoidosis

Files in This Item:
Kitaichi N, Garefes.pdf59.2 kBPDFView/Open
Please use this identifier to cite or link to this item:

Title: Usefulness of quantifying serum KL-6 levels in the follow-up of uveitic patients with sarcoidosis
Authors: Kitaichi, Nobuyoshi Browse this author →KAKEN DB
Ariga, Toshihide Browse this author
Kase, Satoru Browse this author →KAKEN DB
Yoshida, Kauzhiko Browse this author
Namba, Kenichi Browse this author →KAKEN DB
Ohno, Shigeaki Browse this author →KAKEN DB
Keywords: migration inhibitory factor
interstitial pneumonia
ocular involvement
muci mucin
Issue Date: Apr-2006
Publisher: Springer
Journal Title: Graefes archive for clinical and expermental ophthalmology
Volume: 244
Issue: 4
Start Page: 433
End Page: 437
Publisher DOI: 10.1007/s00417-005-0081-9
PMID: 16133026
Abstract: Background: KL-6 is a human glycoprotein secreted by type II alveolar cells in the lung, and its serum levels increase in pneumonia of various causes. We previously reported that serum KL-6 levels in uveitis patients with sarcoidosis were significantly higher than those of other uveitis patients and healthy controls. Additionally, the combined measurement of serum KL-6 and angiotensin converting enzyme (ACE) was useful for screening uveitic patients to diagnose sarcoidosis. The purpose of the present study was to investigate the clinical usefulness of quantifying serum KL-6 levels for following-up the patients with sarcoidosis. Methods: Sera were obtained from 36 uveitic patients diagnosed with sarcoidosis and the same number of healthy volunteers. To examine the influence of systemic medication, we also collected blood samples from four more sarcoidosis patients, who were systemically treated with corticosteroid or angiotensin converting enzyme (ACE) inhibitor, an anti-hypertensive drug. The serum concentration of KL-6 was measured by a human KL-6 electrochemiluminescence immunoassay (ECLIA). Results: The mean KL-6 concentrations of sarcoidosis patients and healthy controls were 449.3 +/- 66.3 (mean +/- SE) and 192.1 +/- 11.3, respectively. The average levels of serum KL-6 were significantly elevated in sarcoidosis patients compared with healthy control subjects (P < 0.001), and there were significant correlations between serum KL-6 and ACE levels in the patients with sarcoidosis (r=0.70 and P < 0.0001). Moreover, serum KL-6 concentrations were less affected by systemic corticosteroid, and unaffected by ACE inhibitory drugs in contrast to ACE levels. Conclusions: Measurement of serum KL-6 in the uveitic patients may be useful to follow-up the diagnosed sarcoidosis, as well as for diagnosing sarcoidosis, because the serum KL-6 level was well correlated with the ACE level, and less affected by systemic medication than ACE levels.
Rights: The origin publication is availabe at
Type: article (author version)
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 北市 伸義

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 - Hokkaido University